Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

CHNA vs. XLV: which is better?

Bottom line

CHNA vs XLV: the short answer

CHNA (Loncar China BioPharma ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.

Updated Nov 19, 2026

CHNA vs XLV side by side

CHNAXLV
TypeETFETF
Fund familyGrayscaleSPDR (State Street)
CategoryHealth Care SectorHealth Care Sector
Expense ratio—0.08%
Annual cost per $10k—$8
10-yr cost on $10k (prospectus)—$103
Max front loadNoneNone
12b-1 fee—0.02%
1-yr return—+14.5%
5-yr return (annualized)—+8.1%
10-yr return (annualized)—+9.8%
Best quarter—+14.5%
Worst quarter—−12.7%
Net assets (fund)—$40.6B
Number of holdings—65
Portfolio turnover—2%
Returns as of—Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Holdings overlap

CHNA and XLV share none of their top holdings.

CHNA top 10

    XLV top 10

    1. Eli Lilly & Co — 16.51%
    2. Johnson & Johnson — 10.64%
    3. AbbVie Inc — 7.74%
    4. UnitedHealth Group Inc — 6.57%
    5. Merck & Co Inc — 5.52%
    6. Amgen Inc — 3.40%
    7. Thermo Fisher Scientific Inc — 3.24%
    8. Abbott Laboratories — 2.75%
    9. Gilead Sciences Inc — 2.73%
    10. Intuitive Surgical Inc — 2.45%

    FAQ

    What is the difference between CHNA and XLV?
    CHNA (Loncar China BioPharma ETF) and XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) are both etfs.
    Should I own both CHNA and XLV?
    Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

    Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.